Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr 10;25(1):241.
doi: 10.1186/s12877-025-05860-6.

Palliative use of midazolam in acute geriatric units: a multicenter ambispective study

Chloé Prod'homme  1 , Guillaume Deschasse  2   3 , Fabien Visade  2   4 , Camille Hennion  5 , Anne Charpentier  5 , Cedric Gaxatte  5 , Frederic Bloch  3 , Celine Delecluse  4 , François Puisieux  2   5 , Jean-Baptiste Beuscart  2   5
Affiliations
Multicenter Study

Palliative use of midazolam in acute geriatric units: a multicenter ambispective study

Chloé Prod'homme et al. BMC Geriatr. .

Abstract

Introduction: End-of-life management in acute geriatric units (AGUs) is frequent but complex. Midazolam is the drug of choice for the management of refractory symptoms (particularly in the context of sedation) at the end of life. The objective of the present ambispective analysis was to investigate the frequency and modalities of midazolam use for palliative care in AGUs in France.

Methods: We conducted a prospective study in four AGUs in France, in order to identify patients having received comfort care only and having been treated with midazolam. We then retrospectively documented the modalities of midazolam use, the indications, and the level of effectiveness.

Results: Of the 210 patients identified as having received comfort care only in the AGU, 68 (32.4% (95%CI, 26.1 to 39.2%)) had received midazolam. The indication for midazolam corresponded to sedation in 67.6% of cases. The modalities of midazolam use at the end -of -life were rarely personalized, with low dose levels (less than 0.5 mg/h), mainly subcutaneous administration, and little anticipatory prescribing or dose level titration. The modalities did not appear to vary with the indication (anxiolysis vs. sedation).

Discussion: The present study is one of the first to have described the frequency and characteristics of palliative midazolam use in the AGU. Our results showed that the end-of-life use of midazolam is rarely personalized, not explicitly documented, and often not compliant with the current guidelines on palliative sedation practices.

Clinical trials registration number: NCT02949635. Registration Date: 2016-09-07.

Keywords: Anti-anxiety agents; Comfort care only; Deep sedations; End-of-life care; Geriatrics; Midazolam; Palliative care.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The DAMAGE study was performed in compliance with the tenets of the Declaration of Helsinki and was approved by an institutional review board (CPP Nord-Ouest IV, Lille, France) on February 13th, 2015. An amendment was approved on January 21st, 2016 (reference: IDRCB 2014 A01670 47, CNIL. bxA15352514). The patients and their primary family caregivers or legal representatives were given detailed verbal and written information about the study, in order to ensure that the patients fully understood the potential risks and benefits of participation. In accordance with the French legislation on observational, non-interventional studies of routine clinical care, written consent was not required. The patients were informed that they could refuse to participate in the study and that refusal would not have any impact on their treatment in the AGU. If the patient was unable to refuse to participate in the DAMAGE study (notably because of severe neurocognitive disorders), the next of kin or legal representative could refuse participation. All participants were free to withdraw from the study at any time. This withdrawal had no impact on the care received. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lucchi E, Milder M, Dardenne A, Bouleuc C. Could palliative sedation be seen as unnamed euthanasia? A survey among healthcare professionals in oncology. BMC Palliat Care. 2023;22:97. - PMC - PubMed
    1. den Hartogh G. Continuous deep sedation and homicide: an unsolved problem in law and professional morality. Med Health Care Philos. 2016;19:285–97. - PMC - PubMed
    1. Surges SM, Garralda E, Jaspers B, Brunsch H, Rijpstra M, Hasselaar J, et al. Review of European guidelines on palliative sedation: A foundation for the updating of the European association for palliative care framework. J Palliat Med. 2022;25:1721–31. - PubMed
    1. de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med. 2007;10:67–85. - PubMed
    1. Tomczyk M, Jaques C, Jox RJ. Clinical practice guidelines on palliative sedation around the world: A systematic review. J Palliat Care. 2022;:082585972211386. - PMC - PubMed

Publication types

Associated data